Herantis Pharma Oyj: 1 director

A director at Herantis Pharma Oyj sold 411,000 shares at 1.500EUR and the significance rating of the trade was 96/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...

Herantis Pharma - Terminating coverage

ABGSC terminates coverage of Herantis Pharma Due to the end of the contractual period Last published estimates are shown in this report

Herantis Pharma - A look back at H1’21

Summary of events in H1’21 Updated model following refocusing on CNS Upcoming milestones

Herantis Pharma - New data presented at virtual R&D day

Herantis hosted a virtual R&D today Internal/external speakers on PD & CDNF/xCDNF New deeper look at xCDNF pre-clinical data the stand-out

Sector Fast Comment - Life Science Summit 2021

50 Nordic life science companies – replay links attached COVID-19 recovery on the agenda AstraZeneca’s EVP Int. on the Chinese market

Herantis Pharma - HER-096: A new name in the pipeline

xCDNF pre-clinical candidate selected Further pre-clinical development to follow Positive pipeline progress

Herantis Pharma - Moving towards a pure play Neuroscience co.

More data presented for Lymfactin and CNS assets Inconclusive Lymfactin results spurs plans to out-license All focus now on CDNF and xCDNF

Herantis Pharma - H2’20 Report

Eventful H2’20 Financials Implications for the share

Herantis Pharma - Inconclusive topline results from AdeLE study

No additional benefit with Lymfactin identified Baseline differences and inconsistent outcome measures Negative market sentiment for now, more details Q2’21

Herantis Pharma - Taking a closer look at the new R&D strategy

Review of new intranasal delivery and clinical programme Growing industry interest in neurology & proteostasis Preview for AdeLE readout in Q1’21

Powerpoint Sector Report - Swedish Biotech Monthly

Herantis Pharma - Gearing up for alternative delivery

Collaboration with Nanoform announced Two PoC studies for enhanced BBB penetration Raises hopes for new administration approach in PD

Powerpoint Sector Report - Swedish Biotech Monthly

Herantis Pharma - Lymfactin Ph I follow-up review announced

Safety and tolerability maintained through to 24 months Observations of clinical benefit at 12 months maintained Ph II AdeLE study to readout in Q1’21

Herantis Pharma - CDNF program pivots towards easier delivery

Intracerebral delivery abandoned More patient friendly methods to be explored A fresh start with an accelerated development trajectory

Powerpoint Sector Report - Biotech Monthly

Herantis Pharma - A closer look at the 12-month Parkinson’s data

Top-line data for CDNF presented without surprises Primary safety endpoint met Plans for next study to determine efficacy in the pipeline

Powerpoint Sector Report - Biotech Monthly

First edition of ABG Sundal Collier's monthly biotech update An overview of the newsflow in August and near-term milestones We highlight IPO activity and returns of the Swedish biotech sector in the last five years

Herantis Pharma - Positive Ph I-II data in 12m follow up

Efficacy signals look promising Improved safety and tolerability Overall positive results from today’s 12m update

Herantis Pharma - H1’20 report

Great progress in the first half of 2020 CDNF program, new data in Q3’20 Lymfactin fully recruited and set for results in Q1’21e